Here’s the thing..
Even if we don’t get the PUL2.0 endpoint but can show a marginal improvement : FDA will give us the green light
Why ?
Because it’s an unmet need and precedent has been set by the FDA with other drugs .. eg Sarepta.
We are still waiting for the fat reduction data
Then we have to consult with the J Foundation..
However
JG was very upbeat about the new diseases Atl1102 can treat..Wont be long before that news will unfold.
anp chart, page-1016
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
